ETFs to Profit from the Weight Loss Drug Boom

Zacks06-04

Two dominant investing themes over the past year have been AI and weight-loss drugs. While there's a lot of excitement around AI, particularly with NVIDIA NVDA, shares of two companies that dominate ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2441255948?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-04 23:45","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2441255948","market":"us","top_or_hot":-1,"title":"ETFs to Profit from the Weight Loss Drug Boom","media":"Zacks","content":"<div>\n<p>Two dominant investing themes over the past year have been AI and weight-loss drugs. While there's a lot of excitement around AI, particularly with NVIDIA NVDA, shares of two companies that dominate ...</p>\n\n<a href=\"https://finance.yahoo.com/news/etfs-profit-weight-loss-drug-154500848.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ETFs to Profit from the Weight Loss Drug Boom</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nETFs to Profit from the Weight Loss Drug Boom\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-04 23:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/etfs-profit-weight-loss-drug-154500848.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Two dominant investing themes over the past year have been AI and weight-loss drugs. While there's a lot of excitement around AI, particularly with NVIDIA NVDA, shares of two companies that dominate ...</p>\n\n<a href=\"https://finance.yahoo.com/news/etfs-profit-weight-loss-drug-154500848.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0943347566.SGD","symbol_name":"安联收益及增长平衡基金AM H2-SGD","start_time":0,"source_url":"https://finance.yahoo.com/news/etfs-profit-weight-loss-drug-154500848.html","article_id":"2441255948","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2441255948","pubTimestamp":1717515900,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Two dominant investing themes over the past year have been AI and weight-loss drugs. While there's a lot of excitement around AI, particularly with NVIDIA NVDA, shares of two companies that dominate the weight-loss drug market have also surged over the past year due to soaring demand for their products.Shares of Eli Lilly LLY are up over 89% over the past year, and its market capitalization surpassed Tesla's TSLA earlier this year. Shares of Novo Nordisk  are up over 73%, making it the biggest European firm by market value.More than 1 billion individuals worldwide are living with obesity, a figure expected to impact over half the population by 2035. Obesity is linked to numerous health risks, including diabetes, heart disease, stroke, and cancer.GLP-1 medications mimic the effects of the naturally occurring hormone glucagon-like peptide-1, which is produced in the intestine after eating. These drugs were initially used to treat diabetes but were later found to control blood sugar level","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE0034235295.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"A\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00BDCRKT87.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"ADC\" (USD) INC","LU0079474960.USD":"联博美国增长基金A","LU0719512351.SGD":"JPMorgan Funds - US Technology A (acc) SGD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","THNR":"AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF","LU0061474960.USD":"天利环球焦点基金AU Acc","HRTS":"Tema Cardiovascular and Metabolics ETF","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","LLY":"礼来","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0058720904.USD":"联博国际健康护理基金A","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","NVDA":"英伟达","BK4587":"ChatGPT概念","LU0882574055.USD":"富达全球健康医疗A ACC","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","OZEM":"Roundhill GLP-1 & Weight Loss ETF","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4579":"人工智能","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","FDN":"First Trust Dow Jones Internet I","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","NVO":"诺和诺德","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC"},"translate_title":"ETF将从减肥药热潮中获利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"THNR":1,"OZEM":1,"HRTS":1,"NVO":1,"NVDA":1,"FDN":0.9,"LLY":0.9},"content_text":"Two dominant investing themes over the past year have been AI and weight-loss drugs. While there's a lot of excitement around AI, particularly with NVIDIA NVDA, shares of two companies that dominate the weight-loss drug market have also surged over the past year due to soaring demand for their products.\nShares of Eli Lilly LLY are up over 89% over the past year, and its market capitalization surpassed Tesla's TSLA earlier this year. Shares of Novo Nordisk (NVO) are up over 73%, making it the biggest European firm by market value.\nMore than 1 billion individuals worldwide are living with obesity, a figure expected to impact over half the population by 2035. Obesity is linked to numerous health risks, including diabetes, heart disease, stroke, and cancer.\nGLP-1 medications mimic the effects of the naturally occurring hormone glucagon-like peptide-1, which is produced in the intestine after eating. These drugs were initially used to treat diabetes but were later found to control blood sugar levels, reduce appetite, and promote weight loss.\nRecent studies suggest that GLP-1 drugs may also slow the progression of Parkinson’s symptoms and reduce the severity of sleep apnea.\nAccording to Goldman Sachs, the market for these drugs could surge to $130 billion by 2030, with Eli Lilly and Novo Nordisk retaining about 80% of the market share.\nThere are 232 anti-obesity medications at various stages of development, according to the Financial Times. The next generation weight-loss drugs aim to reduce costs as well as common side effects like nausea and muscle loss.\nTo learn about the Tema Obesity & Cardiometabolic ETF HRTS, Roundhill GLP-1 & Weight Loss ETF OZEM and Amplify Weight Loss Drug & Treatment ETF THNR , please watch the short video above.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nNVIDIA Corporation (NVDA) : Free Stock Analysis Report\nTesla, Inc. (TSLA) : Free Stock Analysis Report\nTema Obesity & Cardiometabolic ETF (HRTS): ETF Research Reports\nAmplify Weight Loss Drug & Treatment ETF (THNR): ETF Research Reports\nRoundhill GLP-1 & Weight Loss ETF (OZEM): ETF Research Reports\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2441255948"}